Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells $36,242.10 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Oxana Beskrovnaya also recently made the following trade(s):

• On Wednesday, December 11th, Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock. The shares were sold at an average price of $28.12, for a total value of $65,632.08.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $13.17 on Friday. The company has a market cap of $1.34 billion, a P/E ratio of -3.70 and a beta of 1.11. The stock’s 50-day moving average is $17.19 and its 200-day moving average is $27.93. Dyne Therapeutics, Inc. has a 52-week low of $13.05 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on DYN shares. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Friday, January 10th. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics in the third quarter valued at about $34,000. Point72 DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the third quarter valued at about $36,000. US Bancorp DE lifted its stake in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $50,000. Finally, KBC Group NV lifted its stake in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.